# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- disclose government rights

## FIELD OF THE INVENTION

- introduce botulinum neurotoxins

## BACKGROUND OF THE INVENTION

- describe botulism
- discuss current treatments and limitations

## SUMMARY OF THE INVENTION

- introduce neutralizing antibodies
- describe antibody compositions and methods

## Definitions

- define BoNT polypeptide
- define BoNT serotype
- define BoNT subtype
- define anti-BoNT antibody
- define neutralization
- define high affinity
- define antibody structure
- define conservative substitution

## DETAILED DESCRIPTION

- introduce botulinum neurotoxin and its effects
- motivate need for novel antibodies

### I. Potency of Botulinum Neurotoxin (BoNT)-Neutralizing Antibodies.

- describe desired potency of antitoxin

### II. Botulinum Neurotoxin (BoNT)-Neutralizing Antibodies.

- describe characteristics of BoNT-neutralizing antibodies

### III. Preparation of BoNT Neutralizing Antibodies.

- express BoNT-neutralizing antibodies using standard techniques
- synthesize nucleic acids encoding BoNT-neutralizing antibodies
- amplify and clone nucleic acids using molecular cloning techniques
- express anti-BoNT antibodies in recombinantly engineered cells
- prepare whole polyclonal or monoclonal antibodies using immunization and selection techniques
- produce monoclonal antibodies using hybridoma technology

### IV. Modification of BoNT Neutralizing Antibodies.

- use phase display to increase antibody affinity
- create mutant scFv gene repertoires by chain shuffling
- increase affinity of anti-BoNT antibodies by site directed mutagenesis
- create anti-BoNT (scFv')2 homodimers
- prepare anti-BoNT (scFv)2, Fab, and (Fab')2 molecules
- select neutralizing antibodies by screening for specific binding
- select antibodies using immunochromatography or surface plasmon resonance
- measure anti-BoNT antibody affinity for one or more BoNT subtypes
- determine Kd of BoNT-neutralizing antibody and kinetics of binding to BoNT/E

### V. Human or Humanized (Chimeric) Antibody Production.

- motivate humanized antibody production
- describe chimeric antibody production
- outline steps for producing chimeric antibodies
- describe human and humanized antibody production
- outline methods for producing fully human antibodies
- describe trioma technology for producing human antibodies
- outline cloning and expression of antibody genes from trioma cell lines

### VI. Assaying for Cross-Reactivity at a Neutralizing Epitope.

- define cross-reactivity
- describe competitive binding assay
- outline epitope mapping technique

### VII, Assaying for Neutralizing Activity of Anti-BoNT Antibodies.

- describe neutralization assays

### VIII. Diagnostic Assays.

- describe diagnostic assays for botulism
- motivate biological sample selection
- outline immunoassay configurations
- describe non-competitive assay formats
- describe competitive assay formats
- discuss reduction of non-specific binding
- summarize substrate options
- outline other assay formats
- describe labeling of anti-BoNT antibodies

### IX. Pharmaceutical Compositions.

- describe pharmaceutical compositions
- motivate antibody combinations
- outline administration methods

